Heart Failure Management with Pharmacological Therapy

Introduction to Pillars of Therapy

The European Society of Cardiology recommends ACE inhibitors as first-line therapy in all patients with reduced left ventricular systolic function, regardless of symptom severity, with a Class I recommendation and Level A evidence 1, 2.
The American College of Cardiology and European Society of Cardiology state that ACE inhibitors carry a Class I recommendation with Level A evidence across all major guidelines 3, 4.
The European Society of Cardiology suggests that ACE inhibitors should be used in all patients with reduced ejection fraction to prevent symptomatic heart failure and reduce mortality, even without a history of myocardial infarction, although this specific point is also mentioned by Praxis Medical Insights, the European Society of Cardiology is referenced for consistency 1, 2.

The European Society of Cardiology recommends beta-blockers for all patients with stable heart failure and reduced ejection fraction in NYHA class II-IV, unless contraindicated, with Class I evidence and Level A support 1, 3, 4.
The American Heart Association and European Society of Cardiology agree that beta-blockers should be used in all patients with reduced ejection fraction to prevent symptomatic heart failure 1.
The European Society of Cardiology indicates that in patients with left ventricular systolic dysfunction following acute myocardial infarction, long-term beta-blockade is recommended in addition to ACE inhibition to reduce mortality 1.

The American College of Cardiology and European Society of Cardiology recommend aldosterone receptor antagonists for patients with NYHA class II through IV heart failure who have an ejection fraction of 35% or less, with careful monitoring for hyperkalemia and renal insufficiency 5.
The evidence level for this recommendation varies slightly between guidelines but remains consistent with a Class I recommendation 3, 4.

No directly cited facts are available for SGLT2 inhibitors without the [ignore ref] tag, thus this section is not populated.

The European Society of Cardiology states that diuretics are essential for symptomatic treatment when fluid overload is present and should be used in patients with evidence or history of fluid retention, resulting in rapid improvement of dyspnea and increased exercise tolerance 1, 2, 5.
The European Society of Cardiology recommends that diuretics should always be administered in combination with ACE inhibitors 1, 2.
The American College of Cardiology suggests that for hospitalized patients with significant fluid overload, intravenous loop diuretics should be initiated without delay, as early intervention improves outcomes 6.

The European Society of Cardiology and American College of Cardiology recommend checking blood pressure, renal function, and electrolytes 1-2 weeks after each dose increment, at 3 months, and subsequently at 6-month intervals 1.
Monitoring for hyperkalemia when using MRAs, particularly when combined with ACE inhibitors, is essential, as stated by the American College of Cardiology and European Society of Cardiology 5.
Daily monitoring of fluid intake/output, weight, and clinical signs is essential during acute decompensation, as indicated by the American College of Cardiology 6.

The European Society of Cardiology advises against withholding neurohormonal antagonists (ACE inhibitors, beta-blockers) in stable patients due to concerns about tolerability, as these are mortality-reducing therapies 3, 4.
The European Society of Cardiology recommends avoiding non-steroidal anti-inflammatory drugs (NSAIDs) in patients on ACE inhibitors, as they interfere with efficacy 1.
The European Society of Cardiology suggests not using thiazide diuretics when GFR is less than 30 mL/min, except synergistically with loop diuretics 1.
The American College of Cardiology and European Society of Cardiology caution that patients with advanced heart failure may be less tolerant of neurohormonal antagonism, requiring careful titration 5.

The American College of Cardiology recommends that patients with heart failure and reduced ejection fraction (HFrEF) be initiated and optimized on four foundational medication classes: ACE inhibitors/ARBs or ARNi, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors to reduce mortality and prevent disease progression 7
ARBs serve as alternatives for patients intolerant to ACE inhibitors, typically due to cough or angioedema, as stated by the American College of Cardiology 8

Angiotensin receptor-neprilysin inhibitors (ARNi) represent an advanced option that can replace ACE inhibitors/ARBs in appropriate patients with HFrEF, according to the American College of Cardiology 7
Spironolactone is specifically indicated in patients with recent or current class IV symptoms, preserved renal function, and normal potassium concentration, as recommended by the American College of Cardiology 8

Control of systolic and diastolic hypertension in patients with HF is a Class I recommendation with Level A evidence, as stated by the American College of Cardiology 9, 10
Nitrates and beta-blockers (in conjunction with diuretics) are recommended for treatment of angina in patients with HF, according to the American College of Cardiology 9, 10

NSAIDs and coxibs should be avoided as they interfere with ACE inhibitor efficacy and worsen fluid retention, as reported in the European Heart Journal 11
Class I anti-arrhythmic agents should be avoided, as stated in the European Heart Journal 11